The ASIST study will assess the safety and efficacy of BXQ-350 plus SOC, modified FOLFOX7 (mFOLFOX7) and bevacizumab, in patients with newly diagnosed mCRC. The study is also evaluating whether the ...

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on November 13. Debanjana ...

Higher Dimensions of Healing is excited to announce the opening of its Psychedelic Wellness Center, located at 1950 E College ...

An expert has flagged the common signs of diabetes, including a common nighttime habit. As World Diabetes Day was marked on ...

And these data are really quite interesting and impressive that if you don't progress and that your time on [enfortumab ...

Vitamin B6 could help protect against cancer and cognitive decline. Learn more about the benefits of B6 and how to ...

A recent study from the Federal University of São Paulo (UNIFESP) has found that using infrared light along with regular ...

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus ...

University of Sheffield spinout company, Rinri Therapeutics, a company focused on developing new treatments for hearing loss ...

Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis.

Dr Menon believes that lifestyle modifications are “essential in managing diabetes and preventing complications.” His ...